Lista de obras -

A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice

article

A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model

artículo científico publicado en 2016

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

artículo científico publicado en 2007

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax

artículo científico publicado en 2007

Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

artículo científico publicado en 2005

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees

artículo científico publicado en 2013

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania ⬇️

artículo científico publicado el 22 de agosto de 2011

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

artículo científico publicado en 2008

Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model

artículo científico publicado en 2007

Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus

artículo científico publicado en 2006

Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni).

artículo científico publicado en 2014

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

artículo científico publicado en 2002

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

artículo científico publicado en 2002

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines

artículo científico publicado en 2007

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

artículo científico publicado en 2002

Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains

artículo científico publicado en 2005

DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination

scholarly article by Xintao Hu published in September 2018

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge

artículo científico publicado en 2007

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

artículo científico publicado en 2009

Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein.

artículo científico publicado en 2003

Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein

artículo científico publicado en 2003

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

artículo científico publicado en 2002

Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge

artículo científico publicado en 2008

Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses

artículo científico publicado en 2017

Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles

artículo científico publicado en 2004

Elimination of A-type inclusion formation enhances cowpox virus replication in mice: implications for orthopoxvirus evolution

scientific article published on 29 January 2014

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection

artículo científico publicado en 2009

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

artículo científico publicado en 2007

First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

artículo científico publicado en 2018

Generation of Recombinant Vaccinia Viruses

artículo científico publicado en 2015

Generation of Recombinant Vaccinia Viruses

Generation of Recombinant Vaccinia Viruses.

artículo científico publicado en 2017

Genetic studies of the susceptibility of classical and wild-derived inbred mouse strains to monkeypox virus

artículo científico publicado en 2015

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge

article

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial

artículo científico publicado en 2015

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

artículo científico publicado en 2012

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

scholarly article

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

artículo científico publicado en 2004

Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models

artículo científico publicado en 2010

Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.

artículo científico publicado en 2003

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses

artículo científico publicado en 2012

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

artículo científico publicado en 2004

Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

artículo científico publicado en 2009

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

artículo científico publicado en 2012

Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection

artículo científico publicado en 2017

Intradermal HIV-1 DNA immunization using needle-free Zetajet<sup>TM</sup> injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial.

artículo científico publicado en 2017

Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response

artículo científico publicado en 2012

Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge

artículo científico publicado en 2009

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

artículo científico publicado en 2004

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

artículo científico publicado en 2004

Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses

scientific article published on 22 April 2020

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins

artículo científico publicado en 2017

Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface

artículo científico publicado en 2002

Overview of the vaccinia virus expression system

artículo científico publicado en 2002

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques

artículo científico publicado en 2011

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

artículo científico publicado en 2010

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults

artículo científico publicado en 2015

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine

artículo científico publicado en 2010

Preparation of Cell Cultures and Vaccinia Virus Stocks

artículo científico publicado en 2015

Preparation of Cell Cultures and Vaccinia Virus Stocks

artículo científico publicado en 2017

Preparation of Cell Cultures and Vaccinia Virus Stocks

artículo científico publicado en 2017

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

artículo científico publicado en 2011

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys ⬇️

scientific article published on 24 October 2013

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus

artículo científico publicado en 2008

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

artículo científico publicado en 2009

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate

artículo científico publicado en 2007

Rectal Acquisition of SIVmac239 Infection Despite Vaccine-Induced Immune Responses Against the Entire SIV Proteome

artículo científico publicado en 2020

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

artículo científico publicado en 2011

Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost

artículo científico publicado en 2017

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

artículo científico publicado en 2003

Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251...

artículo científico publicado en 2005

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine

artículo científico publicado en 2006

Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging

artículo científico publicado en 2013

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers

artículo científico publicado en 2016

VSV/MVA vaccine rapidly elicits SIV antibodies and local and systemic SIV T cell responses in macaque neonates but does not prevent SIV dissemination after oral challenge

article

Lista de obras de

A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice

A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax

Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania ⬇️

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model

Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus

Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni).

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains

DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein.

Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge

Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses

Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles

Elimination of A-type inclusion formation enhances cowpox virus replication in mice: implications for orthopoxvirus evolution

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Generation of Recombinant Vaccinia Viruses

Generation of Recombinant Vaccinia Viruses

Generation of Recombinant Vaccinia Viruses.

Genetic studies of the susceptibility of classical and wild-derived inbred mouse strains to monkeypox virus

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models

Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection

Intradermal HIV-1 DNA immunization using needle-free Zetajet<sup>TM</sup> injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial.

Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response

Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins

Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface

Overview of the vaccinia virus expression system

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine

Preparation of Cell Cultures and Vaccinia Virus Stocks

Preparation of Cell Cultures and Vaccinia Virus Stocks

Preparation of Cell Cultures and Vaccinia Virus Stocks

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys ⬇️

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate

Rectal Acquisition of SIVmac239 Infection Despite Vaccine-Induced Immune Responses Against the Entire SIV Proteome

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251...

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine

Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers

VSV/MVA vaccine rapidly elicits SIV antibodies and local and systemic SIV T cell responses in macaque neonates but does not prevent SIV dissemination after oral challenge